Multivitamins with Iron Are Generally Safe in G6PD Deficiency
Iron supplementation, including iron-containing multivitamins, is generally safe for patients with G6PD deficiency and does not typically trigger hemolysis. The primary concern in G6PD deficiency is avoiding specific oxidative drugs (like primaquine, rasburicase, nitrofurantoin, and sulfonamides) and fava beans, not routine iron supplementation 1.
Key Evidence Supporting Safety
The available evidence demonstrates that:
Iron itself is not a hemolytic trigger: Large-scale real-world data from over 31,000 G6PD-deficient patients showed that major hemolysis requiring hospitalization occurred in only 0.2% of cases, with 71.8% caused by fava beans, 8.5% by infections, and only 4.2% potentially medication-related (none involving iron) 2.
Iron deficiency is actually common in G6PD patients: Studies show G6PD-deficient individuals maintain normal iron status without iron overload despite chronic low-grade hemolysis 3. Some G6PD-deficient patients have even been inappropriately treated with iron for years without adverse hemolytic events 4.
Standard multivitamin formulations are recommended: Multiple bariatric surgery guidelines recommend routine multivitamin-mineral supplements containing iron (45-60 mg elemental iron daily) without any contraindication for G6PD deficiency 5, 6.
Important Caveats
While iron is safe, be aware of these considerations:
Avoid iron-chelate complexes in oxidative stress: Laboratory studies suggest iron-EDTA complexes may enhance oxidative damage when combined with other oxidizing agents (like divicine from fava beans), though this is not clinically relevant for standard oral iron supplements 7.
Monitor for true hemolytic triggers: Focus on avoiding well-established triggers including:
Consider vitamin E supplementation: If the patient experiences chronic hemolysis, vitamin E (100 IU daily) may provide additional antioxidant protection and reduce hemolytic episodes 9.
Practical Recommendation
Prescribe standard multivitamins with iron without hesitation in G6PD-deficient patients. The typical iron content (18-65 mg elemental iron) poses no hemolytic risk. Focus your counseling on avoiding fava beans and known oxidative medications rather than restricting iron supplementation, which may actually be beneficial if the patient has concurrent iron deficiency from chronic low-grade hemolysis.